Friday 21 January 2011
|
|
08.40-09.00 | Opening address |
09.00-11.00 | Prostate cancer I - Prevention, screening, diagnosis, staging |
09.00-09.20 | Should we be recommending 5ARI’s or diet to prevent prostate cancer? |
09.20-09.40 | The optimal diagnostic strategy? |
09.40-10.00 | Screening: After ERSPC and PLCO; ProTecT will clarify |
10.00-10.20 | The role of MRI in detection, localization, screening and staging |
10.20-11.00 | Debate: |
11.00-11.30 | Coffee Break |
11.30-13.30 | Prostate cancer II - Localised/T3NOMO |
11.30-11.50 | How should we be doing Active Surveillance to prevent understaging and adverse outcome? |
11.50-12.10 | Focal therapy: Hot topic but are there any new data? |
12.10-12.30 | What is the best approach to yield the trifecta after radical prostatectomy. |
12.30 -12.50 | Surgery for high risk localised disease – the role of frozen section of LN and/ or surgical margins |
12.50-13.10 | Revival of immunotherapy for prostate cancer |
13.10-14.10 | Lunch |
14.30-15.30 | Prostate cancer III - Advanced |
14.30-14.50 | Does radical prostatectomy confer survival benefit in LN positive patients? |
14.50-15.10 | Is intermittent hormone therapy better than continuous? |
15.10-15.30 | Are LHRH antagonists better than analogue s? |
15.30-15.50 | ASCO/ESMO news on prostate cancer (to include Abiraterone) |
15.50-16.20 | Coffee Break |
16.20-18.00 | Testis cancer |
16.20-17.00 | Debate: NSGCT post-chemotherapy RPLND: Everybody or nobody? |
17.00-17.20 | ASCO/ESMO news on testis cancer |
17.20-18.00 | Debate: Challenging the EAU Guidelines on testis cancer |
18.00-18.30 | Penile cancer: Penile cancer surgery: Who, how, where? |
|
Saturday 22 January 2011
| Bladder cancer I |
08.30-08.50 | Haematuria: At what point can we ignore it? |
08.50-09.10 | Blue light cystoscopy and narrow band imaging: Who should have it and is it cost-effective? |
09.10-09.30 | Active surveillance for NMIBC: An option? |
09.30-09.50 | Management of G3pT1 disease |
09.50-10.30 | Debate: Challenging the EAU Guidelines on bladder cancer. Early Re-TUR in NMIBC |
10.30-11.00 | Coffee Break |
11.00-13.00 | Renal cancer I |
11.00-11.20 | Laparoscopic radical nephrectomy instead of open partial nephrectomy – a dangerous trend? |
11.20-11.40 | Small renal tumours: the role of biopsy and active surveillance |
11.40-12.00 | Laparoscopic/robotic partial nephrectomy: Trick and tips (videos) |
12.00-12.20 | Focal therapy in RCC: Which modality is best? |
12.20-12.40 | Transvaginal NOTES/ LESS: The future? |
12.40-13.00
| Panel discussion
|
Sunday 23 January 2011
|
Bladder and Upper Tract Cancer II |
09.00-09.20 | Muscle-invasive TCC: Has role of bladder sparing changed in recent years? |
09.20-09.40 | Complications after Radical Cystectomy: Incidence and prevention |
09.40-10.00 | Radical cystectomy and neobladder in the female: Point counterpoint |
10.00-10.20 | Neo or adjuvant chemotherapy: MVAC or GC |
10.20-10.40 | Prognostic factors in Upper Tract TCC |
10.40-11.00 | ASCO/ESMO news on bladder cancer |
11.00-11.30 | Coffee Break |
11.30-13.10 | Renal cancer II |
11.30-11.50 | Surgery for caval and atrial tumor thrombus |
11.50-12.10 | Health economic consequences of targeted therapy in M+ RCC: Are we getting what we are paying for? |
12.10-12.30 | ASCO/ESMO news on renal cancer |
12.30-13.10 | Debate: Challenging the EAU Guidelines on renal cancer |
13.10-13.30 | Award ceremony |
13.30-13.40 | Close |